Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Michael Grossbard, MD

Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Member of the Healthcare Council

Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's lymphoma, breast, gastrointestinal, and colon cancer. Dr. Grossbard has published extensively on the use of immunotherapy for treatment of cancer, and has consulted for companies such as Genentech, IDEC, Berlex, and Amgen. (This is me - Update Profile)


Employment History
2000 - present Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
2000 - present Chief of Hematology-Oncology
ST LUKE'S-ROOSEVELT HOSPITAL CENTER

GLG Study Groups with Michael Grossbard, MD(?)

View All Study Groups with Michael Grossbard, MD

GLG NewsSM Analyses by Michael Grossbard, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
New Agents Needed for Therapy of Neuropathy in Cancer Patients- Is AL-309 the Agent? | 05-19-2008
Analysis of: Allon data demonstrate potential of AL-309 as a new neuropathy treatment | www.pipelinereview.com
Author: Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons

Cancer patients frequently develop neuropathy as a results of chemotherapy agents including oxaliplatin, paclitaxel, vinca alkaloids, and Velcade.  Because many such patients have extended survival or receive treatment with curative intent, the resultant neuropathy can limit quality of life significantly....

Proteosome Inhibition with Carfilzomib is Promising Therapeutic Avenue | 05-19-2008
Analysis of: Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors | www.pipelinereview.com
Author: Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons

Carfilzomib is a nvelo prteosome inhibitor.  Bortezomib, the only proteosome inhibitor that is currently FDA approve, has shown significant activity in myeloma and mantle cell NHL and is being tested in other hematologic malignancies.  If Carfilzomib has improved toxicty and greater efficacy...

Ricin Vaccine Market Relies on Threat of Terror | 05-05-2008
Analysis of: DOR BioPharma Initiates Non-Human Primate Efficacy Studies of RiVaxTM, Its Vaccine Against Ricin Toxin | www.pipelinereview.com
Author: Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons

Ricin is an extraordinarily potent toxin that is fatal because of its ability to inhibit protein synthesis and rapidly cause multisystem failure.  Because ricin can be prepared from castro beans, it has the potential to be used in terrorist attacks.  The present vaccine has the potential to...

Too Early to Draw Conclusions Yet on Vargatef | 05-05-2008
Analysis of: Data suggests promising overall survival and progression-free survival with Vargatef(TM) (BIBF 1120) | www.pipelinereview.com
Author: Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons

Vargatef is a novel angiokinase inhibitor that blocks VEGF, PDGR and FGF receptors.  The current phase II study in patients with non small cell lung cancer shows that this oral agent can be given safely.  It is far too early to draw conclusions regarding efficacy.

View All GLG News SM Analyses by Michael Grossbard, MD

GLG InstituteSM Seminars with Michael Grossbard, MD(?)

 
Michael Grossbard, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Michael Grossbard, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics